Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

AstraZeneca
Baxter
Boehringer Ingelheim
Colorcon
Merck
McKinsey

Last Updated: December 9, 2019

DrugPatentWatch Database Preview

INFLAMASE MILD Drug Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Which patents cover Inflamase Mild, and what generic alternatives are available?

Inflamase Mild is a drug marketed by Novartis and is included in one NDA.

The generic ingredient in INFLAMASE MILD is prednisolone sodium phosphate. There are eighty-eight drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the prednisolone sodium phosphate profile page.

Summary for INFLAMASE MILD
Drug patent expirations by year for INFLAMASE MILD
Synonyms for INFLAMASE MILD
[2-(11,17-dihydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl] dihydrogen phosphate
11beta,17,21-Trihydroxypregna-1,4-diene-3,20-dione 21-(disodium phosphate)
125-02-0
1263143-23-2
A805337
AC1L1J72
AC1L1LDT
AC1L9B41
AKOS025310687
AKOS025394281
AN-14017
API0003920
AT-2935
BCP11881
C21H27O8P.2Na
CHEMBL1201014
Codelsol
Cortisate-20 (Veterinary)
CS-2878
CTK8I0968
D00981
D3918
disodium [2-(11,17-dihydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-yl)-2-oxo-ethyl] phosphate
disodium [2-(11,17-dihydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl] phosphate
disodium [2-[(8S,9S,10R,11S,13S,14S,17R)-10,13-dimethyl-11,17-bis(oxidanyl)-3-oxidanylidene-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-yl]-2-oxidanylidene-ethyl] phosphate
disodium [2-[(8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] phosphate
Disodium prednisolone 21-phosphate
disodium;[2-[(8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] phosphate
DTXSID2047480
EINECS 204-722-9
EINECS 206-120-1
FT-0631728
HY-B0645
Hydeltrasol
I06-0770
Inflamase
Inflamase Forte
IV021NXA9J
KB-296232
LS-118502
LS-174283
Metreton
Millipred
MolPort-019-991-120
NCGC00249889-01
Optimyd
Optival
Pediapred (TN)
Phortisolone
Predair
Predair Forte
Prednesol
Prednisolone (disodium phosphate)
Prednisolone 21-(dihydrogen phosphate)
Prednisolone 21-(disodium phosphate)
Prednisolone 21-phosphate disodium
Prednisolone 21-Phosphate Disodium Salt
Prednisolone disodium phosphate
Prednisolone phosphate sodium
prednisolone sodium phosphate
Prednisolone sodium phosphate (JP17/USP)
Prednisolone Sodium Phosphate [USAN:JAN]
Prednisolone sodium phosphate [USP:JAN]
Predsol
Predsolan
Pregna-1,4-diene-3,20-dione, 11-beta,17,21-trihydroxy-, 21-(dihydrogen phosphate), disodium salt
Pregna-1,4-diene-3,20-dione, 11-beta,17,21-trihydroxy-, 21-(dihydrogen phosphate),disodium salt
Pregna-1,4-diene-3,20-dione, 11,17-dihydroxy-21-(phosphonooxy)-, disodium salt, (11.beta.)-
Pregna-1,4-diene-3,20-dione, 11,17-dihydroxy-21-(phosphonooxy)-, disodium salt, (11beta)-
Prozorin
SCHEMBL1650407
SCHEMBL23563
Sodium prednisolone phosphate
Solucort
ST24049032
UNII-IV021NXA9J
VA11575
Vasocidin Solution
Veripred 20

US Patents and Regulatory Information for INFLAMASE MILD

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis INFLAMASE MILD prednisolone sodium phosphate SOLUTION/DROPS;OPHTHALMIC 080751-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Baxter
AstraZeneca
Express Scripts
Mallinckrodt
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.